CSL shares (ASX: CSL) added 1.16% to around $196.30, more than doubling off the low of the year, as a fresh broker upgrade provided an added boost to holders.
Investors are leaning harder into the recovery narrative, as Morgan Stanley lifted its CSL price target from $182 to $200, building in upside from pipeline assets VMX-C001 and lixudebart and flagging potential earnings upgrades from FY32 onward as those programs mature. Whilst the price target is only just up from here, after a doubling off lows, confirmation that the Street continues to see value is a form of validation for the run.
The operational backdrop is also improving, as earlier this month CSL signed an exclusive global collaboration with Swiss biotech Alentis on lixudebart, a claudin-1 antibody positioned as a potential first-in-class treatment for rare kidney and liver diseases.
CSL committed a US$355 million upfront payment and up to US$1.2 billion in milestones, and will fully fund Phase 2 and Phase 3 trials. Interim Phase 2 data in a small cohort of 26 patients with AAV-associated kidney disease showed encouraging signals on kidney function, though the results are early and not yet fully published. The deal gives the market a nephrology growth story beyond the troubled Vifor iron therapy unit, which absorbed heavy impairments during the reset year, and reinforces CSL Behring’s plasma franchise as the engine room of group earnings.
The rally also comes as healthcare has been leading parts of the ASX, with money rotating toward defensive earnings amid volatility in AI-linked and cyclical names.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
The Setup
The average price target at $186.23 implies a ~5% downside from here, with some struggling to keep pace with the rally. There remain those willing to step in and raise however, with RBC Capital upgrading the stock to Buy with a $213 target last month, and Morgan Stanley doing so to $200.
The technical setup is beginning to look stretched however, with the RSI at 76.63 firmly in overbought territory, and the CCI reading of 235.8 confirms an upside stretch. The stock is also trading above the upper Bollinger band near $191.76, with band width around 10% and 20-day volatility rising sharply, pointing to range expansion. The bullish trend structure remains firmly in tact, with CSL’s share price well above the 50-day average near $173.84, and the 200-day at $143.64.
It has been a mighty rally off the low of A$90 for CSL holders, with the stock undoing a 45%+ decline through the first five months of the year to sit 14.15% higher YTD. One of the more impressive rebounds of recent years is now beginning to look a little stretched, and whilst the technicals may want to cool off a little under A$200, this is a stock that had hit highs above A$300 back in 2024. Can the rally continue, or is a pause in store? We will be keeping a close eye for signs of either.
Bull Case:
- Morgan Stanley and RBC upgrades validate the recovery, with targets up to $213.
- Lixudebart deal adds first-in-class nephrology growth beyond the troubled Vifor franchise.
- Strong uptrend, resilient Behring earnings and buyback support continued momentum.
Bear Case:
- Shares trade above the $186 consensus target, implying modest downside on Street view.
- Overbought technicals raise risk of near-term profit-taking or mean reversion.
- Pipeline earnings are years away; early trial data and execution risks remain.
